Vera Therapeutics Inc.

27.60
-6.58 (-19.25%)
At close: Feb 14, 2025, 3:59 PM
undefined%
Bid 27.46
Market Cap 1.75B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -2.61
PE Ratio (ttm) -10.57
Forward PE n/a
Analyst Buy
Ask 29
Volume 6,102,337
Avg. Volume (20D) 625,453
Open 34.25
Previous Close 34.18
Day's Range 25.99 - 34.50
52-Week Range 25.99 - 51.61
Beta undefined

About VERA

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of ...

Industry Biotechnology
Sector Healthcare
IPO Date May 14, 2021
Employees 82
Stock Exchange NASDAQ
Ticker Symbol VERA

Analyst Forecast

According to 8 analyst ratings, the average rating for VERA stock is "Buy." The 12-month stock price forecast is $64, which is an increase of 131.88% from the latest price.

Buy 87.50%
Hold 12.50%
Sell 0.00%
Stock Forecasts
1 month ago
-6.08%
Vera Therapeutics shares are trading lower. The co... Unlock content with Pro Subscription
3 months ago
-9.23%
Vera Therapeutics shares are trading lower after the company announced plans to commence a public offering to issue and sell $300 million of its Class A common stock.